![Efficacy of the TAK-003 Vaccine for Protection Against Dengue Fever in Children, Adolescents - Infectious Disease Advisor Efficacy of the TAK-003 Vaccine for Protection Against Dengue Fever in Children, Adolescents - Infectious Disease Advisor](https://www.infectiousdiseaseadvisor.com/wp-content/uploads/sites/16/2019/01/denguevaccinegetty512153116_1275958.jpg)
Efficacy of the TAK-003 Vaccine for Protection Against Dengue Fever in Children, Adolescents - Infectious Disease Advisor
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003) | PLOS Neglected Tropical Diseases
![Takeda's dengue shot keeps 84% of kids out of hospital regardless of prior infection, giving it a leg up over Sanofi's Dengvaxia | Fierce Biotech Takeda's dengue shot keeps 84% of kids out of hospital regardless of prior infection, giving it a leg up over Sanofi's Dengvaxia | Fierce Biotech](https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1621828483/mosquito-49141_1280.jpg?VersionId=DQcAl_bX1kHA8ZaDe2kJntpy_p6fsvch)
Takeda's dengue shot keeps 84% of kids out of hospital regardless of prior infection, giving it a leg up over Sanofi's Dengvaxia | Fierce Biotech
![Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial - The Lancet Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/6b2860ee-6f55-4a4c-8cec-a42c75915369/gr1.gif)
Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial - The Lancet
![Takeda's tetravalent dengue vaccine (TAK-003) receives first global approval for use in Indonesia without need for pre-vaccination testing | Asia Research News Takeda's tetravalent dengue vaccine (TAK-003) receives first global approval for use in Indonesia without need for pre-vaccination testing | Asia Research News](https://www.asiaresearchnews.com/sites/default/files/articles_images/syringes-5057119_1280.jpg)
Takeda's tetravalent dengue vaccine (TAK-003) receives first global approval for use in Indonesia without need for pre-vaccination testing | Asia Research News
![Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial](https://medicaldialogues.in/h-upload/2022/06/11/178453-ananya-1500-960px-8.webp)
Takeda dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
![Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration](https://mms.businesswire.com/media/20221122005793/en/1645538/5/takeda-logo_FULL.jpg)
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration
![Structure of: (a) CYD -TDV (Dengvaxia); (b) TAK -003; (c) TV003 / TV005... | Download Scientific Diagram Structure of: (a) CYD -TDV (Dengvaxia); (b) TAK -003; (c) TV003 / TV005... | Download Scientific Diagram](https://www.researchgate.net/publication/356875873/figure/fig1/AS:1098811191640066@1638988411469/Structure-of-a-CYD-TDV-Dengvaxia-b-TAK-003-c-TV003-TV005-Source.png)
Structure of: (a) CYD -TDV (Dengvaxia); (b) TAK -003; (c) TV003 / TV005... | Download Scientific Diagram
PharmaShots. - • The submission is based on a P-III TIDES trial assessing TAK-003 (0.5ml, SC) vs PBO in 20,000+ healthy children & adolescents aged 4-16yrs. to prevent dengue fever of any
![Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003 Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003](https://www.frontiersin.org/files/Articles/452280/fimmu-10-01778-HTML/image_m/fimmu-10-01778-g001.jpg)
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
![Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003 Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003](https://www.frontiersin.org/files/Articles/452280/fimmu-10-01778-HTML/image_m/fimmu-10-01778-g002.jpg)
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
![Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003 Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003](https://www.frontiersin.org/files/MyHome%20Article%20Library/452280/452280_Thumb_400.jpg)
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
![VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | 2 Minute Medicine VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2019/12/2MM_VA_11.17.2019_3.jpg)
VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | 2 Minute Medicine
![Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC](https://europepmc.org/articles/PMC9071282/bin/jiaa761f0003.jpg)
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
![Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results](https://static.bangkokpost.com/media/content/20210524/c1_2120863.jpg)